Pharmacogenomics. 2012;13(13):1523-1535. 5-year survival for stage III and IV (%): carriers, 38.1; noncarriers, 24.5 Median survival: p = 0.002 5-year survival for stage III and IV: p < 0.001 [46 ...

Women with BRCA1 or BRCA2 mutations have a very high lifetime risk of developing breast and ovarian cancer. Women have options to reduce their risk of cancer. Options to reduce breast cancer risk ...

Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.

BOISE — A bill that would require private Idaho health insurers to cover supplemental breast cancer screenings for high-risk ...

A bill that would require private Idaho health insurers to cover supplemental breast cancer screenings for high-risk patients ...

In 1995, our researchers discovered the cancer gene BRCA2, which, when mutated, can make carriers more likely to develop cancer. This discovery means that families can now assess their cancer risk ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Followed categories will be added to My News. She has one of the most commonly inherited gene mutations – BRCA2 – which increases the risk of breast, ovarian and prostate cancers. Mia tested ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

A bill that would require private Idaho health insurers to cover supplemental breast cancer screenings for high-risk patients has advanced to the House floor.

What are the challenges associated with BRCA2 variant testing and analysis? Variant interpretation is challenging in genes where pathogenic mutations predispose a person to breast cancer. This is ...

Glucagon-like peptide 1 (GLP-1) drugs, such as Ozempic, are intended for type 2 diabetes patients and people with obesity, ...